Research
Hormonal
High glucose levels independently regulate gene expression through the transcription factor ChREBP, which is activated by glucose metabolites (xylulose 5-phosphate) to promote lipogenesis and glycolysis, even in the absence of insulin.
High carbohydrate intake directly signals your liver and fat cells to produce fat and break down glucose for energy, independent of insulin levels, via a specific protein (ChREBP).
GoodSupportsHIGH confidence
A new factor... exhibits a GlRE/ChoRE binding activity that could account for glucose responsiveness... renamed the ChoRE binding protein (ChREBP)... A mouse line null mutant for ChREBP provided evidence for a direct and dominant role of ChREBP in the glucose-mediated upregulation of LPK, ACC, and FAS gene transcription... xylulose 5-phosphate from the pentose phosphate pathway is the proposed functional link between high glucose and ChREBP activation.
Why this rating
Strong molecular evidence from knockout mice, but the paper acknowledges the complexity of dissociating glucose and insulin effects.
Source
Transcriptional Regulation of Metabolism
Béatrice Desvergne et al. · Physiological Reviews · 2006
DOI 10.1152/physrev.00025.2005
narrative_reviewCited 897×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Transcriptional regulation by nuclear receptors (specifically PPARs, LXRs, and SREBPs) and transcription factors (ChREBP, FOXOs) serves as the primary long-term mechanism for maintaining metabolic homeostasis by coordinating glucose, lipid, and amino acid metabolism in response to fasting and feeding cycles.Strong
- Insulin signaling promotes lipid synthesis and glucose storage by upregulating SREBP-1c and ChREBP, while simultaneously repressing gluconeogenic genes via the inhibition of FOXO transcription factors.Strong
- Fasting and low glucose levels trigger transcriptional changes that promote gluconeogenesis and fatty acid oxidation via the activation of transcription factors like CREB, PGC1, and PPARs, counteracting insulin's effects.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →